title: Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody.
abstract: Despite promising results in the use of anti-epidermal growth factor receptor (EGFR) Abs for cancer therapy, several issues remain to be addressed. An increasing emphasis is being placed on immune effector mechanisms. It has become clear for other Abs directed to tumor targets that their effects involve the adaptive immunity, mainly by the contribution of Fc region-mediated mechanisms. Given the relevance of EGFR signaling for tumor biology, we wonder whether the oncogene inhibition could contribute to Ab-induced vaccine effect. In a mouse model in which 7A7 (an anti-murine EGFR Ab) and AG1478 (an EGFR-tyrosine kinase inhibitor) displayed potent antimetastatic activities, depletion experiments revealed that only in the case of the Ab, the effect was dependent on CD4(+) and CD8(+) T cells. Correspondingly, 7A7 administration elicited a remarkable tumor-specific CTL response in hosts. Importantly, experiments using 7A7 F(ab')(2) suggested that in vivo Ab-mediated EGFR blockade may play an important role in the linkage with adaptive immunity. Addressing the possible mechanism involved in this effect, we found quantitative and qualitative differences between 7A7 and AG1478-induced apoptosis. EGFR blocking by 7A7 not only prompted a higher proapoptotic effect on tumor metastases compared with AG1478, but also was able to induce apoptosis with immunogenic potential in an Fc-independent manner. As expected, 7A7 but not AG1478 stimulated exposure of danger signals on tumor cells. Subcutaneous injection of 7A7-treated tumor cells induced an antitumor immune response. This is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.
authors: Tumor Immunology Direction, Molecular Immunology Institute, Center of Molecular Immunology, Havana 11600, Cuba. greta@cim.sld.cu
authors: Greta
authors: G
authors: Garrido
authors: Ailem
authors: A
authors: Rabasa
authors: Belinda
authors: B
authors: Sánchez
authors: María Victoria
authors: MV
authors: López
authors: Rances
authors: R
authors: Blanco
authors: Armando
authors: A
authors: López
authors: Diana Rosa
authors: DR
authors: Hernández
authors: Rolando
authors: R
authors: Pérez
authors: Luis Enrique
authors: LE
authors: Fernández
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000502:physiology; D000911:Antibodies, Monoclonal / Q000502:physiology*; D000918:Antibody Specificity / Q000502:physiology*; D017209:Apoptosis / Q000276:immunology*; D018827:Carcinoma, Lewis Lung / Q000276:immunology* / Q000473:pathology / Q000556:secondary; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D005260:Female; D007141:Immunoglobulin Fc Fragments / Q000502:physiology; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D007141:Immunoglobulin Fc Fragments; D066246:ErbB Receptors